Literature DB >> 7200890

Cyclophosphamide, adriamycin and cisplatin combination chemotherapy in advanced bladder carcinoma: an EORTC phase II study.

J H Mulder, S D Fossa, M De Pauw, A T Van Oosterom.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1982        PMID： 7200890     DOI： 10.1016/0277-5379(82)90034-7

Source DB:  PubMed          Journal:  Eur J Cancer Clin Oncol        ISSN： 0277-5379


× No keyword cloud information.
  4 in total

1.  Cooperative studies of systemic chemotherapy. A review of the work of the EORTC Urological Group and of the Yorkshire Urological Cancer Research Group (YUCRG).

Authors:  P H Smith; J A Child; J H Mulder; A T Van Oosterom; J A Martinez-Pineiro; B Richards; G Stoter; O Dalesio; M De Pauw; R Sylvester
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

2.  Phase III trial of the Japanese Urological Cancer Research Group for Adriamycin: cyclophosphamide, adriamycin and cisplatinum versus cyclophosphamide, adriamycin and 5-fluorouracil in patients with advanced transitional cell carcinoma of the urinary bladder.

Authors:  A Maru; H Akaza; S Isaka; K Koiso; T Kotake; T Machida; Y Matsumura; Y Nakagami; T Niijima; K Obata
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

Review 3.  Chemotherapy of advanced transitional-cell carcinoma of the bladder.

Authors:  R S Miller; F M Torti
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

4.  The chemotherapy of advanced bladder cancer.

Authors:  D W Newling; G Stoter; R Sylvester; M de Pauw
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.